Semaglutide Trials Barely Looked at Oral Health Despite Years of Safety Data
A scoping review of 12 semaglutide RCTs confirms mostly gastrointestinal side effects, but no trial directly studied dental or oral outcomes.
Summary
Semaglutide, the GLP-1 drug used for type 2 diabetes and weight loss, is well known for causing nausea and diarrhea. This scoping review searched three databases for randomized trials from 2019 to 2025 and found 12 that met its criteria. Nausea appeared in all 12 trials and diarrhea in 11. Pancreatitis, liver and gallbladder problems were reported in a few trials, with low event counts. Oral side effects were barely documented: dry mouth appeared in one trial and dental caries in another, and none of the trials was designed to study the mouth or teeth. The authors conclude that the drug's safety profile looks favorable overall, but that the evidence on oral health is too thin to draw conclusions. They call for future trials to include standardized dental assessments and longer follow-up.
Detailed Summary
Semaglutide has become one of the most widely used drugs for obesity and type 2 diabetes. Patients and clinicians increasingly report oral complaints such as dry mouth, taste changes and mucosal discomfort, and dentists want to know whether the drug affects oral health. Diabetes and periodontal disease also influence each other, so a metabolic drug could plausibly change gum and tooth outcomes. This review asked what randomized trials actually say about semaglutide's systemic and oral adverse events.
The authors followed PRISMA-ScR guidelines and registered their protocol on OSF. They searched PubMed, Scopus and Web of Science for English-language randomized controlled trials published from 2019 to 2025 in adults with obesity and/or type 2 diabetes. Of 630 records, 10 duplicates were removed and 608 of the remaining 620 were excluded at screening, leaving 12 trials. Two reviewers screened independently, with a third available for arbitration. Data were charted in Excel and not pooled, and certainty of evidence was not graded.
Seven trials used subcutaneous semaglutide, three used oral semaglutide and two used mixed routes. Planned treatment lasted 21 to 68 weeks, clustering between 40 and 52 weeks, with 4 to 9 weeks of follow-up. Nausea was reported in all 12 trials and diarrhea in 11. Constipation appeared in 9 trials and vomiting in 8. Pancreatitis was reported in 5 trials, hepatobiliary events in 3 and gallbladder disease in 3, all with low absolute counts. Nasopharyngitis (5 trials) and COVID-19 (5 trials) likely reflect background infection rather than drug effects.
The individual trial tables show clear dose and comparator patterns. In Davies 2021, semaglutide 2.4 mg produced nausea in 33.7% of participants versus 9.2% on placebo, and vomiting in 21.8% versus 2.7%. In Aroda 2025, discontinuation for adverse events reached 23% on 8 mg versus 2% on placebo. Oral formulations showed high event counts, and the authors note a higher frequency of adverse events than with injectables.
Oral findings were sparse. Dental caries was reported in one trial (Yamada 2020), in 1 to 3 participants per semaglutide arm and in 2 placebo participants. Dry mouth was reported in one trial (Aroda 2025), at roughly 5% on 2 mg and 3% on 8 mg, with none on 16 mg or placebo. These percentages were estimated visually from a supplementary figure. A single submandibular abscess occurred in the placebo group. No trial assessed salivary flow, periodontal status or erosion, so the authors treat these findings as incidental.
The authors argue that repeated vomiting could expose teeth to gastric acid and that dry mouth may reflect reduced body water or nasopharyngitis-related mouth breathing. Caries and erosion develop slowly, and most follow-up periods were too short to capture them. Semaglutide might even benefit periodontal health by improving glycemic control and weight. They recommend that future trials and real-world cohorts include standardized oral assessments, including xerostomia, salivary flow, periodontal pocket depth, caries and validated oral quality-of-life questionnaires, with longer follow-up and collaboration between endocrinologists, dentists and pharmacologists.
Key Findings
- Of 630 records screened, only 12 RCTs met the criteria, and none directly investigated oral or dental outcomes.
- Nausea appeared in all 12 trials and diarrhea in 11, followed by constipation (9 trials) and vomiting (8 trials).
- Pancreatitis was reported in 5 trials, hepatobiliary events in 3 and gallbladder disease in 3, with low absolute event counts.
- In Davies 2021, semaglutide 2.4 mg caused nausea in 33.7% of participants versus 9.2% on placebo, and vomiting in 21.8% versus 2.7%.
- In Aroda 2025, discontinuation due to adverse events was 23% on 8 mg and 18% on 16 mg, versus 2% on placebo.
- Dental caries was reported in 1 trial (1 to 3 participants per semaglutide arm versus 2 on placebo) and dry mouth in 1 trial (about 5% at the 2 mg dose, estimated from a figure).
- Seven trials used subcutaneous semaglutide, 3 used oral and 2 used mixed routes, over 21 to 68 weeks with only 4 to 9 weeks of follow-up.
Methodology
This was a scoping review following PRISMA-ScR, with a protocol registered on OSF. PubMed, Scopus and Web of Science were searched for English-language RCTs from 2019 to 2025 in adults with obesity and/or type 2 diabetes receiving oral or subcutaneous semaglutide. Two reviewers screened independently using Rayyan, with a third for arbitration. Data were narratively charted rather than pooled, and no risk-of-bias or certainty-of-evidence grading was done.
Study Limitations
Only 12 English-language RCTs were included, and the search strategy was not externally peer reviewed. Oral outcomes were secondary or unreported, the studies were heterogeneous in dose, route and comparator, and some data were estimated visually from figures. Follow-up was short for slow processes such as caries and erosion, and oral signs may have predated enrollment. The authors did not pool data or grade evidence certainty, and no conflicts of interest were stated in the supplied text.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
